Betamethasone

Overview

Betamethasone (Celestone®) is a long-acting synthetic glucocorticoid used in dogs and cats for its potent anti-inflammatory and immunosuppressive effects. It is approximately 25 to 40 times more potent than hydrocortisone and has no clinically significant mineralocorticoid activity.

For systemic or intra-articular use, betamethasone is commonly administered as an injectable formulation combining betamethasone sodium phosphate (rapid onset) and betamethasone acetate (prolonged duration). This dual formulation provides both prompt therapeutic effect and sustained anti-inflammatory action.

Mechanism of Action (MOA): Betamethasone binds intracellular glucocorticoid receptors, altering gene transcription and suppressing production of inflammatory mediators. It decreases capillary permeability, inhibits leukocyte migration, stabilizes lysosomal membranes, suppresses cytokine production, and reduces immune responses. It also influences carbohydrate, protein, and fat metabolism and suppresses endogenous ACTH production with prolonged systemic use.

Indications

Betamethasone is used in dogs and cats when a potent, long-acting glucocorticoid is required for anti-inflammatory or immunosuppressive effects. Injectable formulations provide both rapid and sustained activity.

• Anti-inflammatory therapy (systemic use): Used for control of inflammatory and immune-mediated conditions when a long-acting injectable glucocorticoid is preferred. May be administered IV, IM, or PO depending on formulation and clinical indication.
• Control of pruritus – Dogs: Labeled (historically) for short-term control of pruritic inflammatory conditions. Relief following injectable administration may last several weeks.
• Intra-articular administration: May be used for management of joint inflammation and pain when localized glucocorticoid therapy is desired. Some systemic absorption occurs.
• Prenatal therapy – Dogs (extra-label): Maternal administration late in gestation (approximately days 55–57 post-ovulation) may improve pulmonary function in preterm puppies by enhancing gas exchange capacity.

Dosage (Reference)

Dog

In dogs, betamethasone may be administered parenterally (IV or IM) or orally depending on the clinical indication. Because it is a highly potent, long-acting glucocorticoid, dosing frequency is typically less frequent than shorter-acting steroids.

Cat

Cats generally require higher glucocorticoid doses than dogs for equivalent clinical effect but tend to develop fewer adverse effects. Betamethasone is administered systemically for anti-inflammatory indications.

Warnings & Precautions

Betamethasone is a potent, long-acting glucocorticoid with prolonged biologic activity. Careful patient selection, dose limitation, and appropriate monitoring are essential to minimize adverse effects, particularly with repeated or systemic administration.

• Hypersensitivity: Contraindicated in patients with known hypersensitivity to betamethasone or any component of the formulation.
• Active infections: Systemic glucocorticoids are generally contraindicated in systemic fungal infections and should be avoided in the presence of uncontrolled bacterial or viral infections due to immunosuppressive effects.
• Septic arthritis: Intra-articular administration is contraindicated in infected joints.
• Systemic absorption after local use: Injectable joint administration can result in systemic absorption; systemic precautions still apply.
• Cardiac disease: Use cautiously in patients with congestive heart failure or pre-existing cardiac disease, as glucocorticoids may promote fluid retention and increase blood pressure.
• Chronic kidney disease: Use cautiously in patients with renal disease due to potential fluid and electrolyte effects.
• Diabetes mellitus: Glucocorticoids antagonize insulin action and may precipitate or worsen diabetes; monitor closely in diabetic or high-risk patients.
• Gastrointestinal disease: Use cautiously in patients with pre-existing GI ulceration or history of GI disease; risk of ulceration increases with concurrent NSAID use.
• Growth suppression: May delay growth in young, developing animals.
• HPA axis suppression: Prolonged systemic therapy suppresses endogenous ACTH and cortisol production. Gradual tapering is required after chronic administration to prevent adrenal insufficiency.
• Stress events: Animals undergoing tapering or recently discontinued from long-term therapy may require supplemental glucocorticoids during periods of stress (e.g., surgery, trauma, illness).
• Pregnancy: Teratogenic effects have been reported with corticosteroids. Administration during late gestation may induce premature labor.
• Route restriction: Injectable suspension formulations should not be administered intravenously.

Drug Interactions

Clinically significant interactions with betamethasone are primarily associated with systemic administration and reflect its glucocorticoid effects on immune function, electrolyte balance, metabolism, and gastrointestinal integrity. The following interactions are reported or theoretical and may be clinically relevant in dogs and cats.

• NSAIDs (e.g., carprofen, meloxicam, aspirin): Increased risk of gastrointestinal ulceration or bleeding when used concurrently.
• Insulin and oral antidiabetic agents: Glucocorticoids antagonize insulin action; insulin requirements may increase.
• Potassium-depleting diuretics (e.g., furosemide, thiazides): Increased risk of hypokalemia.
• Digoxin: Risk of digitalis toxicity may increase if glucocorticoid-induced hypokalemia develops.
• Amphotericin B: Concurrent use may increase risk of hypokalemia.
• Cyclosporine: Mutual inhibition of hepatic metabolism may increase blood concentrations of both drugs.
• Cyclophosphamide: Glucocorticoids may inhibit hepatic metabolism; dosage adjustments may be required.
• Azole antifungals (e.g., ketoconazole, itraconazole): May decrease glucocorticoid clearance, increasing systemic exposure.
• Phenobarbital or rifampin: May increase glucocorticoid metabolism and reduce efficacy.
• Salicylates: Glucocorticoids may reduce salicylate blood levels and increase GI ulcer risk.
• Vaccines (modified-live): Immunosuppressive dosages of glucocorticoids may reduce vaccine efficacy or increase risk of vaccine-associated infection.
• Cholestyramine: May increase glucocorticoid clearance and reduce therapeutic effect.
• Estrogens: May decrease glucocorticoid clearance.
• Mitotane: May alter glucocorticoid metabolism; higher glucocorticoid doses may be required in patients treated with mitotane.
• Theophylline: Altered pharmacologic effects of either drug may occur.

Side Effects & Overdose

Side Effects

Adverse effects of betamethasone are primarily associated with systemic exposure and are dose- and duration-dependent. Effects resemble those seen with other potent glucocorticoids and may occur even with intermittent long-acting injections.

• Polyuria, polydipsia, polyphagia (PU/PD/PP): Common, even with short-term therapy in dogs.
• Weight gain and panting (dogs): Frequently observed with repeated or prolonged administration.
• Gastrointestinal effects: Vomiting, diarrhea, and increased risk of GI ulceration, particularly at immunosuppressive dosages or with concurrent NSAIDs.
• Elevated liver enzymes: Increased ALT and ALP may occur; hepatocellular glycogen accumulation is possible.
• Behavioral changes: Depression, lethargy, or aggression may be seen.
• Muscle wasting and weakness: Associated with prolonged systemic exposure.
• Delayed wound healing and increased infection risk: Due to immunosuppressive effects.
• Diabetes mellitus (especially cats): Glucocorticoids may induce or worsen diabetes; development of PU/PD/PP in cats warrants evaluation.
• Growth suppression: May occur in young, developing animals.
• Ocular effects (prolonged use): Increased intraocular pressure or cataract formation may occur with chronic systemic exposure.

Overdose

Acute overdoses of glucocorticoids rarely cause life-threatening effects. Clinical signs typically reflect exaggerated pharmacologic actions of the drug.

• Exaggerated PU/PD/PP: Increased thirst, urination, and appetite.
• Gastrointestinal irritation: Vomiting or diarrhea may occur.
• Hyperglycemia: Particularly in predisposed or diabetic patients.
• Management: Supportive care is recommended, including fluid therapy and gastrointestinal protection as needed.

Key Notes

Practical clinical considerations for the safe and strategic use of betamethasone in dogs and cats:

• Dual-component injection: The combination of betamethasone sodium phosphate (rapid onset) and betamethasone acetate (prolonged effect) provides both immediate and sustained activity after a single administration.
• High glucocorticoid potency: Approximately equivalent to dexamethasone on a milligram basis (0.75 mg betamethasone ≈ 0.75 mg dexamethasone), making precise dosing essential.
• No mineralocorticoid activity: Lacks clinically significant sodium-retaining effects compared with some other corticosteroids.
• Very long biologic half-life: Exceeds 300 hours, meaning physiologic effects may persist well beyond detectable plasma concentrations.
• Appetite stimulation: May increase appetite independent of anti-inflammatory action.
• Laboratory interpretation: Does not cross-react with cortisol assays, which is relevant when evaluating adrenal function.
• Thyroid testing impact: Can suppress TSH and reduce T3/T4 concentrations, potentially affecting interpretation of thyroid panels.
• Metabolic effects: Promotes gluconeogenesis and redistribution of body fat with prolonged systemic exposure.